Why Adaptimmune Therapeutics, Atreca, and CRISPR Therapeutics All Tanked In MarchThe Motley Fool • 04/06/20
CRISPR Therapeutics AG (CRSP) Beats Q4 Earnings and Revenue EstimatesZacks Investment Research • 02/12/20
CRISPR Therapeutics Shows Market Leadership With Jump To 92 RS RatingInvestors Business Daily • 02/11/20
CRISPR Therapeutics AG (CRSP) Stock Moves -0.9%: What You Should KnowZacks Investment Research • 01/31/20